

## Special Issue

# Palliative Radiotherapy in Cancer

### Message from the Guest Editors

Palliative radiotherapy is well known for being an essential tool for symptom relief in patients with advanced cancer. However, little space is usually given to this resource in conference events and more generally in the education and permanent training of doctors and specialists working in oncology.

Furthermore, clinical research has only marginally addressed this issue, leaving large spaces without clear scientific evidence in a scenario in which the introduction of the concept of oligometastatic disease has produced gray areas without clear guidelines. Finally, the diffusion of palliative therapies makes it urgent to define paths of integration between pharmacological-supportive treatments and radiotherapy.

We hope that this Special Issue will gather and highlight the evidence needed to help optimize clinical practice in palliative radiotherapy and in particular to improve the integration of radiotherapy with other resources available today in the field of palliative therapies. We look forward to your contributions.

---

### Guest Editors

Prof. Dr. Marco Cesare Maltoni

Prof. Dr. Alessio Giuseppe Morganti

Dr. Romina Rossi

Costanza Maria Donati

---

### Deadline for manuscript submissions

closed (10 March 2024)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/172370](https://mdpi.com/si/172370)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)